Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 475

1.

Beta-blockers in the management of hypertension: focus on nebivolol.

Wojciechowski D, Papademetriou V.

Expert Rev Cardiovasc Ther. 2008 Apr;6(4):471-9. doi: 10.1586/14779072.6.4.471. Review.

PMID:
18402537
2.

Nebivolol: a third-generation beta-blocker for hypertension.

Cheng JW.

Clin Ther. 2009 Mar;31(3):447-62. doi: 10.1016/j.clinthera.2009.03.007. Review.

PMID:
19393838
3.

Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics.

Agabiti Rosei E, Rizzoni D.

Drugs. 2007;67(8):1097-107. Review.

PMID:
17521213
4.

Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.

Van Bortel LM, Fici F, Mascagni F.

Am J Cardiovasc Drugs. 2008;8(1):35-44.

PMID:
18303936
5.

Nebivolol: a review.

Cockcroft J.

Expert Opin Pharmacother. 2004 Apr;5(4):893-9. Review.

PMID:
15102571
6.

Nebivolol: impact on cardiac and endothelial function and clinical utility.

Toblli JE, DiGennaro F, Giani JF, Dominici FP.

Vasc Health Risk Manag. 2012;8:151-60. doi: 10.2147/VHRM.S20669. Epub 2012 Mar 13. Review.

7.

[Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].

von Fallois J, FaĆ¼lhaber HD.

Fortschr Med Orig. 2000 Jul 27;118 Suppl 2:77-82. German.

PMID:
15700490
8.

Nitric oxide mechanisms of nebivolol.

Maffei A, Lembo G.

Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. doi: 10.1177/1753944709104496. Epub 2009 May 14. Review.

PMID:
19443516
9.

The role of the new beta-blockers in treating cardiovascular disease.

Weber MA.

Am J Hypertens. 2005 Dec;18(12 Pt 2):169S-176S. Review.

PMID:
16373195
10.

Nebivolol: third-generation beta-blockade.

de Boer RA, Voors AA, van Veldhuisen DJ.

Expert Opin Pharmacother. 2007 Jul;8(10):1539-50. Review.

PMID:
17661735
11.

Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.

Weiss R.

Vasc Health Risk Manag. 2006;2(3):303-8. Review.

12.

Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.

Gupta S, Wright HM.

Cardiovasc Ther. 2008 Fall;26(3):189-202. doi: 10.1111/j.1755-5922.2008.00054.x. Review.

PMID:
18786089
13.

Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release.

Kamp O, Metra M, Bugatti S, Bettari L, Dei Cas A, Petrini N, Dei Cas L.

Drugs. 2010;70(1):41-56. doi: 10.2165/11530710-000000000-00000.

PMID:
20030424
14.

Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.

Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH.

Clin Exp Pharmacol Physiol. 2007 Apr;34(4):327-31.

PMID:
17324145
15.

Nebivolol: a third-generation beta-adrenergic blocker.

Veverka A, Nuzum DS, Jolly JL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1353-60. Epub 2006 Jul 5. Review.

PMID:
16822893
16.

[Role of the L-arginine/nitric oxide system in the action of nebivolol].

Brodde OE, Philipp T.

Dtsch Med Wochenschr. 2006 Nov 10;131(45):2545-50. Review. German.

PMID:
17091442
17.

Metabolic effects and safety profile of nebivolol.

Pessina AC.

J Cardiovasc Pharmacol. 2001 Dec;38 Suppl 3:S33-5. Review.

PMID:
11811391
18.
19.

Nebivolol: a review of its clinical and pharmacological characteristics.

Gielen W, Cleophas TJ, Agrawal R.

Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. Review.

PMID:
16961165
20.

The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol.

Bakris GL, Basile JN, Giles TD, Taylor AA.

Am J Med. 2010 Jul;123(7 Suppl 1):S2-8. doi: 10.1016/j.amjmed.2010.04.012. Review.

PMID:
20609695

Supplemental Content

Support Center